ArticleNature2022
Deciphering the immunopeptidome in vivo reveals new tumour antigens.
Abstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed.
- TopBP1 orchestrates PU.1-IRF8 transcriptional programming of dendritic cell differentiation and Flt3L-driven tumor immunity.Experimental & molecular medicine · 2026Article
- Immunopeptidome profiling in pulmonary fibrosis provides a platform for identifying therapeutic targets.Nature immunology · 2026Article
- Review
- Engineering TCR-directed T-cells for the treatment of multiple myeloma.Frontiers in immunology · 2026Review
- Defects in antigen processing and presentation: mechanisms, immune evasion and implications for cancer vaccine development.Nature reviews. Immunology · 2026Review
- Computational prediction of human genetic variants in the mouse genome.Nature biotechnology · 2025Article
- Structure guided analysis of KRAS G12 mutants in HLA-A*11:01 reveals a length encoded immunogenic advantage in G12D.Communications biology · 2025Article
- Immunopeptidome analysis reveals SERPINB3 as an autoantigen driving eczematized psoriasis.Science advances · 2025Article
- Overcoming resistance to anti-PD-L1 immunotherapy: mechanisms, combination strategies, and future directions.Molecular cancer · 2025Review
- Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations.Trends in cancer · 2025Review
- Targeting macrophages in cancer immunotherapy: Frontiers and challenges.Journal of advanced research · 2025Review
- The RNA-Binding Protein RBMX Mediates the Immunosuppressive Microenvironment of Osteosarcoma by Regulating CD8Cancers · 2025Article
- Immunologic specificity in glioblastoma: Antigen discovery and translational implications.Neuro-oncology advances · 2025Review
- Tumor antigens preferentially derive from unmutated genomic sequences in melanoma and non-small cell lung cancer.Nature cancer · 2025Article
- CTG-Initiated Cryptic Peptide Translation Up- and Downstream of a Canonical ATG Start Codon Is Enhanced by TLR Stimulation and Induces Tumor Regression in Mice.Cancer immunology research · 2025Article
- Deciphering antigen-specific T cell navigation tactics and cancer immune evasion in co-cultures.Communications biology · 2025Article
- Computational modeling of human genetic variants in mice.bioRxiv : the preprint server for biology · 2025Article
- Reversing the "cold" tumor microenvironment: the role of neoantigen vaccines in prostate cancer.Journal of translational medicine · 2025Article
- Deciphering the MHC immunopeptidome of human cancers with Ligand.MHC atlas.Briefings in bioinformatics · 2025Article
- Personalized neoantigen vaccines in urologic malignancies.Nature cancer · 2025Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Alex M JaegerDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Lauren E StopferDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-6984-3004
Ryuhjin AhnDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9788-4401
Emma A SandersDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Demi A SandelDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-4095-2036
William A Freed-PastorDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-7377-2111
William M RideoutDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Santiago NaranjoDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Tim FessendenDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Kim B NguyenDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Peter S WinterDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Ryan E KohnDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Peter M K WestcottDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-9436-4857
Jason M SchenkelDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Sean-Luc ShanahanDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.
Alex K ShalekDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-5670-8778
Stefani SprangerDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-3257-4546
Forest M WhiteDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-1545-1651
Tyler JacksDavid H. Koch Institute for Integrative Cancer Research, Cambridge, MA, USA. tjacks@mit.edu.ORCID http://orcid.org/0000-0001-5785-8911
Funding
VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Andreea O'Connell · 1985 to 2026
$93.9MTRAINING GRANTS IN ENVIROMENTAL TOXICOLOGYT32ES007020 · NIEHS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI ESSIGMANN, JOHN M · 1985 to 2024
$13.1MElucidating the molecular and cellular mechanisms of immune evasion in pancreatic cancerK08CA259621 · NCI · DANA-FARBER CANCER INST · PI WILLIAM A FREED-PASTOR · 2022 to 2026
$1.1MExploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responsesR00CA241072 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI JAEGER, ALEX · 2022 to 2024
$742kExploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responsesK99CA241072 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI JAEGER, ALEX · 2020 to 2021
$300kHoward Hughes Medical InstituteNCI NIH HHS K08 CA259621NCI NIH HHS K99 CA241072NCI NIH HHS P30 CA014051NCI NIH HHS R00 CA241072NIEHS NIH HHS T32 ES007020
Abstract
Immunosurveillance of cancer requires the presentation of peptide antigens on major histocompatibility complex class I (MHC-I) molecules
Indexed as
Antigens, NeoplasmPeptidesProteomicsAlveolar Epithelial CellsAnimalsAntigen PresentationCarcinoma, Pancreatic DuctalCD8-Positive T-LymphocytesHistocompatibility Antigens Class ILung NeoplasmsMicePancreatic NeoplasmsRNA, MessengerAntigens, NeoplasmHistocompatibility Antigens Class IPeptidesRNA, Messenger
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.